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Introduction
Abnormal immune responses have been found in many indi-
viduals with schizophrenia, regardless of disease stage or 
medication status.1 This is also linked to the hypothesis that 
schizophrenia can originate from early exposure to micro-
bial infections, which may contribute to the etiology through 
chronic neuroinflammatory and autoimmune processes.2,3 
However, current antipsychotic medications show lim-
ited immunomodulatory effects.4 Recent clinical trials have 
attempted to target schizophrenia-related immune activa-
tion using anti-inflammatory agents. Supplementation with 
celecoxib, acetylsalicylic acid, and minocycline in addition 
to standard antipsychotic medication has resulted in overall 
patient improvement, in particular in a reduction in positive 
psychotic symptoms.5–7 However, the number of the immu-
nomodulatory compounds tested to improve symptoms in 
schizophrenia is small, and further studies are required in 
this field.
Probiotics are beneficial microorganisms that modulate 
the immune response of the host by affecting the composition 
of gut microbiota.8 Several probiotic species have been tested 
for health benefits, including the gram-positive anaerobic 
genres Lactobacillus and Bifidobacterium. These have shown 
beneficial effects on systemic inflammatory cytokine levels,9 
neurotransmitter and neurotrophic factor production,10 inte-
sti nal permeability,11 and oxidative stress in animal models.12 
In humans, oral administration of probiotics is known to re store 
normal inflammatory status,13 increase systemic antioxi dant 
capacity,14 change the activity of brain regions responsible 
for processing of emotion and sensation,15 and reduce anxi-
ety.16 Improved brain function after probiotic supplementation 
has been attributed to the gut–brain axis, ie, multiple ways 
of communication between bacteria inhabiting the human 
intestine and the central nervous system.17,18 For example, 
probiotic microorganisms interact with the innate immune 
system, affecting secretion of pro- and anti-inflammatory 
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cytokines which, in turn, can regulate brain development and 
function.19 In addition, bacteria of the species Lactobacillus and 
Bifidobacterium are capable of producing neurotransmitters 
such as gamma-aminobutyric acid (GABA) and acetylcho-
line, which directly target receptors in the central nervous sys-
tem.20 Therefore, probiotics have been suggested as a potential 
novel therapeutic approach for a range of neurodevelopmental 
disorders.21
We recently carried out a clinical trial to assess whether 
supplementation of probiotic strains Lactobacillus rhamnosus 
GG and Bifidobacterium lactis Bb12 can reduce symptom 
severity in schizophrenia patients remaining on long-term 
antipsychotic treatment.22 The present follow-up study 
was undertaken to examine the systemic immunomodula-
tory effects of probiotic supplementation in the same patient 
population. Using multiplexed immunoassays, we measured 
the levels of 47 immune molecules in patient sera collected 
before and after treatment with adjunctive probiotics or pla-
cebo. Group comparisons revealed probiotic-specific changes 
in levels of molecules involved in innate and adaptive immune 
responses and intestinal epithelial cell function. These altera-
tions may be related to improved function of the intestinal 
tract in the probiotic arm of the trial reported before.22
Materials and Methods
Participants and study procedures. The patient popula-
tion and probiotic compound investigated in this study have 
been described in detail previously.22 Briefly, 65 outpatients 
from psychiatric rehabilitation programs in the Baltimore 
area (MD, USA) diagnosed with schizophrenia or schizoaf-
fective disorder according to DSM-IV criteria, with at least 
moderately severe psychotic symptoms [Positive and Negative 
Syndrome Scale (PANSS) positive score $1, PANSS negative 
symptom score $4, or total PANSS score $50, containing at 
least three positive or negative items with scores $3 at screen-
ing] were enrolled in the study between December 2010 and 
August 2012. Participants were randomized into a double-blind 
14-week treatment protocol with adjunctive probiotic (n = 33) 
or placebo (n = 32), with initial 2-week placebo run-in (Fig. 1). 
All patients received antipsychotic treatment for at least eight 
weeks prior to starting the trial and did not change the medica-
tion within the previous 21 days. Patients suffering from any 
clinically significant or unstable medical condition, including 
congestive heart failure, celiac disease, or immunodeficiency 
syndromes, as well as those receiving antibiotics within the 
previous 14 days were excluded from the study.
The active study compound consisted of one tablet con-
taining approximately 109 colony forming units of the probi-
otic organism L. rhamnosus GG and 109 colony forming units 
of the probiotic organism Bifidobacterium animalis subsp. lactis 
BB12 (Ferrosan) or placebo. The probiotic microorganisms 
were grown in media that do not contain casein, lactose, other 
milk products, or gluten, to reduce the risk of allergic reactions 
to these ingredients.
In total, 58 participants completed the trial, compris-
ing 31 in the probiotic arm and 27 in the placebo arm. Blood 
samples were collected from all subjects at the beginning and 
at the end of the trial. Serum was prepared by allowing clot 
Analyzed (n = 27)
Lost to follow up (n = 5):
• 2 withdrew consent • 2 withdrew consent
• 1 outlier excluded
Analyzed (n = 30):
• 3 did not adhere to protocol
Allocated to 14 weeks of adjunctive placebo
(n = 32)
Assessed for eligibility (n = 84)
2 week placebo run-in (n = 65)
Randomized (n = 65)
Allocated to 14 weeks of adjunctive probiotics
(n = 33)
Lost to follow up (n = 2):
Enrollment
Allocation
Follow-up
Analysis
figure 1. CONSORT (Consolidated Standards of Reporting Trials) flow diagram of the trial.
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formation for two hours at room temperature and subsequent 
centrifugation at 4000g for five minutes. The resulting serum 
supernatants were stored at -80 °C until analysis.
Multiplexed immunoassays. Serum samples were analyzed 
using the Human InflammationMAP panel in a Clinical 
Laboratory Improvement Amendments (CLIA)-certified lab-
oratory (Myriad RBM). The panel consisted of 47 multiplexed 
immunoassays targeting selected inflammatory markers, 
including cytokines, chemokines, and acute-phase reactants 
(Table 1A). Analyte levels were estimated in each sample from 
the 8-point standard curves, and assay performance was vali-
dated using three control samples. The same multiplex immu-
noassay platform has been applied successfully for serum bio-
marker profiling in a range of high-impact studies.23–25
Data analysis. For those participants who completed the 
double-blind phase, immune marker data acquired from mul-
tiplex immunoassay analyses were filtered separately for each 
treatment group and time point. Principal component analysis 
was applied to identify artifactual effects on the overall variance. 
One extreme outlier was detected outside of the Hotelling’s 
T2 ellipse showing 95% confidence intervals26 in the probi-
otic-supplemented group and was removed from the analysis. 
Molecules with more than 60% low values were excluded from 
further analysis to allow a minimum of 10 measurements per 
comparison group. This equated to 20 analytes (Table 1A). For 
the 27 analytes remaining in the dataset, missing values were 
replaced with half the minimum value for that specific assay. 
Shapiro–Wilk tests showed that the majority of analyte levels 
were non-normally distributed and a large proportion (30%) 
remained non-normally distributed after log10-transformation. 
Therefore, a non-parametric Wilcoxon signed-rank test was 
applied to compare analyte levels before and after treatment. 
Resulting P-values were controlled for false discovery rate with 
a conservative Benjamini–Hochberg approach.27
Pathway analysis was performed using the ingenuity 
pathways knowledge database (IPKB; Ingenuity® Systems). 
Only molecules from the datasets that met the P-value cut-
off of 0.10 and were associated with the biological functions 
and/or canonical pathways in the IPKB were considered for 
the analysis. A right-tailed Fisher’s exact test was used to cal-
culate P-values associated with the identified pathways. The 
significance of the association between the dataset and canon-
ical pathways was measured by the ratio between the number 
of molecules from the dataset divided by the total number of 
known molecules in that pathway and by the P-value (Fisher’s 
exact test).
Ethical considerations. The study was approved by Insti-
tutional Review Board of the Sheppard Pratt Health Sys-
tem and the Johns Hopkins School of Medicine. The 
trial was registered at ClinicalTrials.gov corresponding to 
NCT01242371 and monitored by a data safety monitoring 
board. Written informed consent was obtained from all study 
participants. The research complied with the principles of the 
Declaration of Helsinki.
results
A total of 65 patients were enrolled in the study and random-
ized, 33 to the adjunctive probiotics arm and 32 to the adjunc-
tive placebo arm. A total of 58 participants (89%) completed 
the study (Fig. 1). The clinical characteristics of the completers 
are shown in Table 1. There were no significant differences in 
age, gender, race, duration of education, PANSS scores, and 
proportion of patients receiving clozapine between the groups 
at the beginning of the study.22 PANSS psychiatric symptom 
scores did not change over the course of the trial, but patients 
receiving probiotic supplement were less likely to report severe 
bowel difficulties (P = 0.003).22
In terms of the mechanism of action, treatment with 
probiotics significantly decreased the levels of the acute-phase 
reactant von Willebrand factor (vWF; Table 2). Uploading the 
accession numbers of all analytes, which showed a change at a 
significance level of ,0.10 [vWF, monocyte chemotactic pro-
tein-1 (MCP-1), brain-derived neurotrophic factor (BDNF), 
T-cell-specific protein RANTES, and macrophage inflam-
matory protein-1 beta (MIP-1 beta)] into the IPKB (www.
ingenuity.com), indicated that supplementation with probi-
otics most significantly affected the regulation of cytokine 
production in macrophages, T helper cells and intestinal epi-
thelial cells by IL-17A and IL-17F pathways (top canonical 
pathways, P = 9.34E – 06 and 1.54E – 05, ratio 0.111 and 
0.087; Table 3). Missing values for the proteins included in 
pathway analysis ranged between 0 and 31%.
Changes identified in the placebo group [vascular cell 
adhesion molecule 1 (VCAM-1) and intercellular adhe-
sion molecule 1 (ICAM-1); Table 2] may have resulted from 
abnormally high levels of these proteins at baseline and there-
fore cannot be assigned as true placebo effects. Initial levels 
of VCAM-1 in the placebo group were 21% higher than in 
the group supplemented with probiotics (P = 0.021, Mann–
Whitney test). After treatment, VCAM-1 returned to simi-
lar levels (3% difference, P = 0.581), with the greatest change 
Table 1. Demographical and clinical data of study completers. the 
table shows mean values ± standard deviation. Detailed description 
of this patient population can be found in ref. 22.
PRobIoTIC  
SuPPlEmEnT
PlACEbo  
SuPPlEmEnT
p-vAluE
n 31 27 –
age 44.8 ± 11.2 48.1 ± 9.4 0.236a)
gender (male/female) 22/9 16/11 0.413b)
race (white/other) 16/15 20/7 0.106b)
Panssc) total start 67.3 ± 11.9 70.2 ± 11.6 0.258a)
Panssc) total end 66.8 ± 11.6 67.3 ± 11.9 0.773a)
CrPd) start (µg/ml) 6.7 ± 8.2e) 6.3 ± 7.6 0.829a)
CrPd) end (µg/ml) 7.1 ± 7.9 7.3 ± 10.1e) 0.841a)
notes: amann–Whitney U test. bFisher’s exact test. cPositive and negative 
syndrome scale. dC-reactive protein. eone outlier excluded.
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Table 3. A list of canonical pathways most significant to the probiotic 
and placebo groups revealed by ingenuity Pathway analysis. only 
proteins that met the P-value cut-off of 0.10 were considered for the 
analysis. Significance of the association was measured by P-value 
and by the ratio of the involved molecules. Probiotic supplementation 
showed enrichment in iL-17a- and iL-17F-related pathways.
PRobIoTIC SuPPlEmEnT PlACEbo SuPPlEmEnT
Differential regulation of Cytokine  
Production in macrophages and  
t helper Cells by iL-17a and iL-17F
(P = 9.34e-06, ratio = 1.11e-01)
atherosclerosis signaling
(P = 2.54e-08,  
ratio = 3.1e-02)
Differential regulation of Cytokine  
Production in intestinal epithelial  
Cells by iL-17a and iL-17F
(P = 1.54e-05, ratio = 8.7e-02)
Leukocyte extravasation  
signaling
(P = 2.37e-05, ratio = 1.6e-
02)
role of hypercytokinemia/ 
hyperchemokinemia in the  
Pathogenesis of Influenza
(P = 4.99e-05, ratio = 4.9e-02)
role of macrophages,  
Fibroblasts and endothelial  
Cells in rheumatoid arthritis
(P = 8.33e-05,  
ratio = 1.0e-02)
role of iL-17 a in arthritis
(P = 8.7e-05, ratio = 3.3e-02)
hmgB1 signaling
(P = 4.3e-04,  
ratio = 2.1e-02)
role of maPk signaling in the  
Pathogenesis of Influenza
(P = 1.3e-04, ratio = 3.0e-02)
hepatic Fibrosis/hepatic  
stellate Cell activation
(P = 9.31e-04,  
ratio = 1.4e-02)
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observed for patients with the highest initial VCAM-1 levels 
(Spearman’s rho = ‑0.61, P = 0.0007). This suggests that 
changes in the placebo group may be because of the regression 
to the mean effect.28,29 In contrast, the levels of vWF at the 
end of the trial were 11% lower in the probiotic arm, suggest-
ing a true change in vWF levels by probiotics.
discussion
This is the first study to investigate the immunomodula-
tory effects of probiotic supplementation in schizophrenia. In 
this investigation, 65 patients undergoing long-term antip-
sychotic treatment were randomized to 14 weeks of either 
probiotic or placebo add-on supplementation and 58 partici-
pants completed the trial (Fig. 1). Using multiplexed immu-
noassays, we measured levels of 47 immune markers before 
and after add-on treatment, of which 27 satisfied the strict 
criteria for analysis. We found that probiotic supplementa-
tion significantly reduced levels of vWF, and levels of MCP-1, 
BDNF, T-cell-specific protein RANTES, and MIP-1 beta 
were found to be increased with borderline significance 
(P # 0.08). These changes were related mostly to the regula-
tion of cytokine production in macrophages, T helper cells, 
and intestinal epithelial cells as shown by the effects on IL-17A 
and IL-17F pathways. Although IL-17 levels were not detect-
able in our study, we identified a trend toward increased levels of 
other cytokines related to IL-17, namely MCP-1 and RANTES. 
The decreased levels of VCAM-1 and ICAM-1 in the placebo 
group were interpreted as regression to the mean effect,28,29 ie, 
they resulted from abnormally high initial levels in the placebo 
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pathophysiology.36 However, an increase in BDNF levels did 
not translate into improved symptoms in the probiotic arm and 
requires further validation to show statistical significance.
Several limitations of the molecular profiling results 
should be considered when interpreting the results of this study. 
First, we were not able to detect all targeted cytokines in our 
clinical samples. This included molecules that have previously 
been shown to be altered in schizophrenia and modulated by 
probiotics, such as IL-1 beta, IL-6, TNF-alpha, and IFN-
gamma. Owing to relatively high P- and q-values (q = 0.431 
for P , 0.1 in the probiotic arm), the identified changes require 
further validation studies. Repeating these experiments using 
more sensitive and diverse multiplex immunoassays is essen-
tial to provide a more complete picture of the effects. Second, 
although we investigated only patients who remained on sta-
ble, long-term antipsychotic treatment during the trial period, 
it is still possible that the antipsychotic compound exhibited 
certain immunomodulatory effects. This relates in particular to 
the changes identified in VCAM-1 and ICAM-1 levels in the 
placebo group. Furthermore, because of the lack of a control 
group, it was not possible to determine whether baseline levels 
of the analytes were altered. In addition, the small number 
of analytes identified as significantly or borderline different 
between the two groups was a limiting factor for the pathway 
analysis, and more complex immune networks may be affected 
by probiotic supplementation. For example, although pathway 
analysis revealed that probiotic supplementation may affect the 
function of intestinal cells, further studies with more specific 
markers are required to assess whether probiotics can attenu-
ate gastrointestinal inflammation.
We conclude that probiotics have immunomodulatory 
effects in schizophrenia patients, affecting molecules that do 
not respond to standard antipsychotic therapy. These changes 
may be associated with the improvement in bowel function-
ing reported previously in the same group of patients through 
IL-17-related immune responses, which control the intes-
tinal microbiome–host interaction. However, supplementa-
tion of probiotics does not reduce psychotic symptoms. We 
suggest that future studies should be carried out that test the 
exact biological and neurobiological mechanisms of probiotic 
supplementation.
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group and did not differ between the groups at the end of the 
study. This is consistent with the fact that the placebo was pro-
vided in the context of long-term stable antipsychotic treatment, 
and therefore, no changes were expected in this group.
The only molecule that changed when applying con-
ventional significance criteria (P , 0.05) after probiotic 
supplementation was vWF (FC = 0.84). vWF is a positive 
acute-phase reactant produced by endothelial cells in response 
to injury and plays an important role in blood coagulation. 
This protein has been found to be positively correlated with 
cardiovascular risk factors in schizophrenia and bipolar dis-
order, and does not change with second-generation antipsy-
chotic treatment.30 In our study, probiotic supplementation 
decreased the levels of vWF. Probiotics are known to decrease 
levels of certain cardiovascular risk parameters.31 However, 
their effect on cardiovascular risk and antipsychotic-related 
thromboembolism32 should be assessed in future longitudi-
nal studies by measuring more specific cardiovascular and 
coagulation markers, such as D-dimer, triglycerides, high-
density lipoprotein (HDL), and low-density lipoprotein 
(LDL).
Pathway analysis suggested that probiotic add-on treat-
ment, but not standard antipsychotic therapy, modulates 
immune function via type 17 immune responses. This path-
way involves the IL-17 family of cytokines, which are regula-
tory proteins produced by T helper 17 (Th17) cells involved in 
cellular responses to extracellular bacteria such as those colo-
nizing the intestinal lumen.33 Therefore, we hypothesize that 
the observed cytokine changes are related to improved bowel 
functioning, which we reported in this group of patients pre-
viously.22 These cytokines are also critical mediators of auto-
immune reactions. Deregulation of the type 17 response has 
been observed in schizophrenia. Studies have shown that this 
pathway was blunted in psychotic episodes.34 Also, autoim-
mune processes against central nervous tissue components, 
which are regulated by type 17 cytokines, are a known phe-
nomenon that may contribute to schizophrenia etiology and/or 
pathology.35 Here, we showed that molecules associated with 
the type 17 response, in particular MCP-1 and RANTES, 
increased with borderline significance in the group of patients 
treated with probiotic supplement. Pathway analysis suggested 
that these changes may be associated with improved control 
of gastrointestinal leakage mediated through the innate and 
adaptive immune systems. This is consistent with the observed 
decrease in vWF levels after probiotic supplementation, which 
might be a secondary effect of improved intestinal epithelium 
integrity. IL-17 levels were not detectable in any of the sam-
ples (,5 pg/mL). Therefore, further studies using assays with 
improved sensitivity are necessary to identify any direct effects 
on T helper type 17 pathways.
The finding that BDNF was increased with borderline 
significance by probiotic add-on treatment is interesting as 
it is a neurotrophin involved in neuronal survival and plas-
ticity and has been associated previously with schizophrenia 
Tomasik et al
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Appendix
Table 1A. Inflammatory markers measured using Human InflammationMAP multiplexed immunoassay platform. Analytes excluded from the 
analysis because of high proportion of missing values are shown in gray.
PRoTEIn unIPRoTKb Id PRoTEIn unIPRoTKb Id
alpha-1-antitrypsin (aat) P01009 interleukin-10 (iL-10) P22301
alpha-2-macroglobulin (a2macro) P01023 interleukin-12 subunit p40 (iL-12p40) P29460
Beta-2-microglobulin (B2m) P61769 interleukin-12 subunit p70 (iL-12p70) P29459
Brain-Derived neurotrophic Factor (BDnF) P23560 interleukin-15 (iL-15) P40933
C-reactive Protein (CrP) P02741 interleukin-17 (iL-17) Q16552
Complement C3 (C3) P01024 interleukin-18 (iL-18) Q14116
eotaxin-1 P51671 interleukin-23 (iL-23) Q9nPF7
Factor Vii P08709 Macrophage Inflammatory Protein-1 alpha  
(miP-1 alpha)
P10147
Ferritin (Frtn) P02794,
P02792
Macrophage Inflammatory Protein-1 beta  
(miP-1 beta)
P13236
Fibrinogen P02671,
P02675,
P02679
matrix metalloproteinase-2 (mmP-2) P08253
granulocyte-macrophage Colony-stimulating  
Factor (gm-CsF)
P04141 matrix metalloproteinase-3 (mmP-3) P08254
haptoglobin P00738 matrix metalloproteinase-9 (mmP-9) P14780
intercellular adhesion molecule 1 (iCam-1) P05362 monocyte Chemotactic Protein 1 (mCP-1) P13500
interferon gamma (iFn-gamma) P01579 stem Cell Factor (sCF) P21583
interleukin-1 alpha (iL-1 alpha) P01583 T-Cell-Specific Protein RANTES (RANTES) P13501
interleukin-1 beta (iL-1 beta) P01584 tissue inhibitor of metalloproteinases 1 (timP-1) P01033
interleukin-1 receptor antagonist (iL-1ra) P18510 tumor necrosis Factor alpha (tnF-alpha) P01375
interleukin-2 (iL-2) P60568 tumor necrosis Factor beta (tnF-beta) P01374
interleukin-3 (iL-3) P08700 tumor necrosis factor receptor 2 (tnFr2) P20333
interleukin-4 (iL-4) P05112 Vascular Cell adhesion molecule-1 (VCam-1) P19320
interleukin-5 (iL-5) P05113 Vascular endothelial growth Factor (VegF) P15692
interleukin-6 (iL-6) P05231 Vitamin D-Binding Protein (VDBP) P02774
interleukin-7 (iL-7) P13232 von Willebrand Factor (vWF) P04275
interleukin-8 (iL-8) P10145
 
Table 2A. Changes in immune marker levels following probiotic and placebo supplementation. FC – average fold change; P-value ,0.05 was 
considered significant (in bold); q-value – P-value controlled for false discovery rate with Benjamini–hochberg procedure.
AnAlYTE funCTIona) PRobIoTIC SuPPlEmEnT PlACEbo SuPPlEmEnT
fC p vAluE q-vAluE fC p-vAluE q-vAluE
von Willebrand Factor aP ↓ 0.84 0.047 0.431 ↑ 1.15 0.751 0.881
monocyte Chemotactic Protein 1 C ↑ 1.22 0.054 0.431 ↓ 0.93 0.525 0.782
Brain Derived neurotrophic Factor gF ↑ 1.28 0.063 0.431 ↑ 1.06 0.895 0.966
T Cell Specific Protein RANTES C ↑ 1.28 0.069 0.431 ↓ 0.96 0.551 0.782
Macrophage Inflammatory Protein 1 beta C ↑ 1.1 0.080 0.431 ↓ 0.97 0.62 0.821
Factor Vii o ↑ 1.05 0.221 0.759 ↓ 0.92 0.117 0.450
Ferritin aP ↓ 0.91 0.225 0.759 ↓ 0.85 0.073 0.450
Vascular endothelial growth Factor gF ↑ 1.08 0.225 0.759 ↑ 1.01 0.957 0.994
stem Cell Factor gF ↑ 1.06 0.285 0.855 ↓ 0.91 0.243 0.513
haptoglobin aP ↓ 0.93 0.365 0.876 ↑ 1.04 0.4 0.720
(Continued)
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Table 2A. (Continued)
AnAlYTE funCTIona) PRobIoTIC SuPPlEmEnT PlACEbo SuPPlEmEnT
fC p-vAluE q-vAluE fC p-vAluE q-vAluE
Fibrinogen aP ↓ 0.95 0.375 0.876 ↑ 1.02 0.511 0.782
Complement C3 aP ↓ 0.96 0.421 0.876 ↓ 0.93 0.247 0.513
interleukin 8 C ↓ 0.95 0.449 0.876 ↑ 1.03 0.713 0.875
interleukin 1 receptor antagonist C ↑ 1.04 0.559 0.876 ↓ 0.83 0.104 0.450
alpha 2 macroglobulin aP ↑ 1.02 0.581 0.876 ↑ 1.02 1.000 1.000
Vascular Cell adhesion molecule 1 o ↑ 1.02 0.584 0.876 ↓ 0.88 0.016 0.313
Beta 2 microglobulin tr ↓ 0.99 0.589 0.876 ↓ 0.93 0.139 0.461
alpha 1 antitrypsin aP ↑ 1.03 0.613 0.876 ↓ 0.98 0.638 0.821
interleukin 18 C ↑ 1.03 0.65 0.876 ↓ 0.9 0.343 0.661
Vitamin D Binding Protein o ↑ 1.02 0.713 0.876 ↓ 0.95 0.234 0.513
interleukin 23 C ↑ 1.02 0.727 0.876 ↓ 0.88 0.154 0.461
eotaxin 1 C ↑ 1.02 0.757 0.876 ↓ 0.96 0.431 0.727
tumor necrosis factor receptor 2 tr ↑ 1.01 0.758 0.876 ↓ 0.87 0.072 0.450
intercellular adhesion molecule 1 tr ↑ 1.03 0.805 0.876 ↓ 0.83 0.023 0.313
matrix metalloproteinase 3 o ↓ 0.98 0.811 0.876 ↓ 0.88 0.099 0.450
tissue inhibitor of metalloproteinases 1 o ↑ 1.02 0.914 0.949 ↓ 0.93 0.242 0.513
C reactive Protein aP ↓ 0.44 0.992 0.992 ↑ 1.54 0.882 0.966
aAbbreviations: aP, acute-phase protein; C, cytokine; gF, growth factor; tr, transmembrane receptor; o, other.
